Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors
Conclusions: Cixutumumab was associated with favorable safety and PK profiles. A dosing regimen of 10 mg/kg every 2 weeks was recommended for subsequent disease-focused clinical trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Electrocardiogram | Insulin | Investigational New Drugs | Study